SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2013 / Cilt: 38 - Sayı: 1

Assessment of platelet aspirin responsiveness in Turkish Population with PFA-100, serum thromboxane B2 , soluble CD40 ligand and soluble P-Selectin]

Türk Populasyonunda aspirin cevapsızlığının PFA-100, serum tromboksan B2 , çözünür CD40 Ligand ve çözünür P-Selektin ile değerlendirilmesi

Beyhan ÖMER
Sema GENÇ
Nilgün ERTEN
Cemil TASÇIOĞLU
Bülent SAKA
Aytaç KARADAĞ
Leyla KILIÇ
Hacer EROĞLU
Timur AKPINAR
Bulent Saka MD
Pages
63–67
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients with aspirin non-responsiveness according to the PFA-100 showed significantly higher serum TBX2, sCD40L and sP-selectin (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Recurrent thromboembolic vascular events have been reported in 5.5 to 60% of the population despite aspirin therapy.
📊
Key Findings & Data:We aimed to determine the frequency of aspirin nonresponsiveness in our population with “Platelet Function Analyzer-100 Closure Time” (PFA100 CT) and serum tromboxane B2, soluble CD40 Ligand and soluble P-selectin levels.
💡
Conclusion & Impact:Patients with aspirin non-responsiveness according to the PFA-100 showed significantly higher serum TBX2, sCD40L and sP-selectin (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Recurrent thromboembolic vascular events have been reported in 5.5 to 60% of the population despite aspirin therapy. We aimed to determine the frequency of aspirin nonresponsiveness in our population with “Platelet Function Analyzer-100 Closure Time” (PFA100 CT) and serum tromboxane B2, soluble CD40 Ligand and soluble P-selectin levels. Material and Methods: Patients (n=118) taking 80-300 mg/day aspirin were enrolled into the study. PFA-100 of 66 healthy people was used to predict cut-off value in our population. PFA-100 test results and serum TXB2, sCD40L and sP-selectine levels of the patients were compared with each other. A TXB2 level of ≥80 ng/ml was accepted as an indicator of aspirin non-responsiveness. Results: According to PFA-100, 40% of the patients revealed aspirin non-responsiveness which was found 8% with serum TXB2 levels. Patients with aspirin non-responsiveness according to the PFA-100 showed significantly higher serum TBX2, sCD40L and sP-selectin (p

Özet

Amaç: Aspirin tedavisi alan hastalarda tekrarlayan tromboembolik olayların sıklığının toplumda %5.5-60 olduğu bildirilmiştir. Bu çalışmada, toplumumuzdaki aspirin cevapsızlığı sıklığının "Platelet Function Analyzer-100 (PFA-100)" kapanma süresi (CT), serum tromboksan B2 (TXB2), sCD40 ligand ve sP-selektin düzeyleri ile taranması amaçlanmıştır. Materyal ve metod: Günlük 80-300 mg aspirin kullanmakta olan hastalar (n=118) çalışmaya alındı. Sağlıklı 66 bireyin PFA-100 CT'si kullanılarak toplumumuz için "cut-off" değeri belirlendi. Hastaların PFA-100 test sonuçları, serum TXB2, sCD40L ve sP-selektin düzeyleri ölçülerek birbirleriyle karşılaştırıldı. Bu esnada TXB2 düzeyinin >=80 ng/ml olması aspirin cevapsızlığının bir göstergesi olarak kabul edildi. Bulgular: PFA-100 testine göre hastaların %40'nda, serum TXB2 sonuçlarına göre ise hastaların %8'inde aspirin cevapsızlığı bulundu. PFA-100 testine göre cevapsız hastalarda serum TXB2, sCD40L ve sP-selektin düzeyleri aspirine duyarlı olan kişilere göre daha yüksek bulundu (p

🔖

Cite This Article

ÖMER, B., GENÇ, S., ERTEN, N., TASÇIOĞLU, C., SAKA, B., KARADAĞ, A., KILIÇ, L., EROĞLU, H., AKPINAR, T., MD, B. S. (2022). Assessment of platelet aspirin responsiveness in Turkish Population with PFA-100, serum thromboxane B2 , soluble CD40 ligand and soluble P-Selectin]. Türk Biyokimya Dergisi, Cilt: 38 - Sayı: 1, 63–67. https://ajindex.com/articles/621314

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. FitzGerald G. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 2003; 361(9357):542-4
  2. Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101(10):1206- 18
  3. Hoogendijk EMG, ten Cate JW. Aspirin and platelets. Lancet 1980; 1(8159):93-4
  4. Jakubowski JA, Stampfer MJ, Vaillancourt R, Deykin D. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol 1985; 60(4):635-42
  5. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation a particulate fraction protein. J Clin Invest 1975; 56(3):624-32
  6. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71(3):676-88
  7. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25(12):2331-6
  8. Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 1994; 118(8):801-4
  9. Bhatt DL. Aspirin resistance: more than just a laboratory curiosity. J Am Coll Cardiol 2004; 43(6):1127-9
  10. Campbell CL, Steinhubl SR. Variability in response to aspirin. Do we understand the clinical releavance. J Thromb Haemost 2005; 3(4):665-9
  11. Pamukcu B, Oflaz H, Onur I, Oncul A, Umman B, et al. Aspirinresistant platelet aggregation in a cohort of patients with coronary heart disease. Blood Coagul Fibrinolysis 2007; 18(5):461-5
  12. Sanderson S, Emery J, Baglin T, Kinmoth AL. Narrative Review: Aspirin resistance and its clinical implications. Ann Intern Med 2005; 142(5):370-80
  13. Roller RE, Dorr A, Ulrich S, Pilger E. Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100. Blood Coagul Fibrinolysis 2002; 13(4):277-81
  14. Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Thrombolysis 2006; 4(4):813–9
  15. Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci USA 2000; 97(25):13835-40
  16. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Förster R et al. CD40 ligand on activated platelets